The response deadline has passed. Review the details for future reference or to track similar opportunities.
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program. Erin Greninger,
Point of Contact Greg Smith Contracting 鈥橬EILL HOUSE (No Street Address
2) WASHINGTON, DC 20515 USA to this opportunity. 75A50126R00002 Amendment 0001.pdf
Get matched to contracts like this daily
Free AI-powered contract matching for your business.